Just as we said yesterday -- it may be tough to get a premium price here.
From Reuters, overnight:
. . . .The potential for Grastek, an oral allergy drug made by Denmark's ALK Abello and American partner Merck, will depend on the product's label and price in tihe United States, chief executive Jens Bager told Reuters on Friday. . . .
It may be material to ALK-Abelló -- but not to Merck.
No comments:
Post a Comment